secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quoin Pharmaceuticals, Ltd. (QNRX)
CIK:        0001671502
Form:       8-K
Filed at:   2024-12-10T23:59:59+00:00
Accession:  0001104659-24-127208
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 3.03, 5.02, 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quoin shareholders approve charter amendments and executive compensation; board grants options
--------------------------------------------------------------------------------

- Shareholders approved amendments to Articles reducing quorum to 33 1/3% (25% for foreign private issuers) and aligning special meeting provisions.
- CEO Myers: 2024 base $662,475, FY23 bonus $301,125, option for 536,603 ADSs at $0.78.
- COO Carter: 2024 base $529,980, FY23 bonus $240,900, option for 536,609 ADSs at $0.78.
- CFO Dunn: 2024 base $433,620, FY23 bonus $197,100, option for 338,994 ADSs at $0.78; non-employee directors each received option for 57,014 ADSs at $0.78.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671502/000110465924127208/0001104659-24-127208-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671502/000110465924127208/tm2430603d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-127208

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer